Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 4/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274850 | 1.00 | NOS1 (0.40) | NOS1NOS3NOS2LTA4HCYP1A2 | |
| SCHEMBL1817108 | 1.00 | NOS1 (0.40) | NOS1NOS3NOS2LTA4HCYP1A2 | |
| Hydrochloric Acid SCHEMBL23510221 | 0.98 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HCYP1A2 | |
| Hydrochloric Acid SCHEMBL15608414 | 0.98 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HCYP1A2 | |
| Hydrochloric Acid SCHEMBL16798190 | 0.98 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HCYP1A2 | |
| SCHEMBL16798263 | 0.93 | KIF11 (0.41) | NOS1NOS3NOS2CYP2C19SLC7A5 | |
| SCHEMBL15201168 | 0.93 | KIF11 (0.41) | NOS1NOS3NOS2CYP2C19SLC7A5 | |
| SCHEMBL13640174 | 0.93 | NOS1 (0.36) | NOS1NOS3NOS2LTA4HCYP1A2 | |
| SCHEMBL14227057 | 0.93 | NOS1 (0.36) | NOS1NOS3NOS2LTA4HCYP1A2 | |
| SCHEMBL8975399 | 0.93 | KIF11 (0.41) | NOS1NOS3NOS2CYP2C19SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002393-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | IMMUNOGEN, INC. (US) | 2017-01-05 | — | — | US | claimed |
| EP-3077522-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | Immunogen, Inc. (US) | 2016-10-12 | — | — | EP | claimed |
| WO-2015085003-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | IMMUNOGEN, INC. (US) | 2015-06-11 | — | — | WO | claimed |
| US-8450089-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2013-05-28 | — | — | US | claimed |
| CN-120115098-A | Method for producing polyamide microcapsules | 弗门尼舍有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-11945862-B2 | Compositions and methods for antibody production | IMMUNOGEN, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220055006-A1 | PROCESS FOR PREPARING POLYAMIDE MICROCAPSULES | FIRMENICH SA (CH) | 2022-02-24 | — | — | US | disclosed |
| EP-3897957-A1 | PROCESS FOR PREPARING POLYAMIDE MICROCAPSULES | Firmenich SA (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3897956-A1 | POLYAMIDE MICROCAPSULES | Firmenich SA (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113226532-A | Polyamide microcapsules | 弗门尼舍有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113195091-A | Method for producing polyamide microcapsules | 弗门尼舍有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20130338225-A1 | Compounds As L-Cystine Crystallization Inhibitors And Uses Thereof | NEW YORK UNIVERSITY (US) | 2013-12-19 | — | — | US | disclosed |
| US-8450089-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110177173-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-21 | — | — | US | disclosed |
| WO-2011062640-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2005113573-A2 | METHOD OF SUPPORT-BASED CHEMICAL SYNTHESIS | MIXTURE SCIENCES, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| EP-1147127-A4 | VOLATILIZABLE SOLID PHASE SUPPORTS FOR COMPOUND SYNTHESIS | MIXTURE SCIENCES INC (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1147127-A1 | VOLATILIZABLE SOLID PHASE SUPPORTS FOR COMPOUND SYNTHESIS | Mixture Sciences Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000046238-A1 | VOLATILIZABLE SOLID PHASE SUPPORTS FOR COMPOUND SYNTHESIS | MIXTURE SCIENCES, INC. (US) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945862-B2 | Compositions and methods for antibody production | TXNRD1, P4HB, CYBB | NOS1 668/4885NOS3 738/4885NOS2 622/4885 |
| US-20130338225-A1 | Compounds As L-Cystine Crystallization Inhibitors And Uses Thereof | GLS, PKD1, CTSA | NOS1 1059/4885NOS3 2115/4885NOS2 1944/4885 |
| US-20110177173-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | GLS, PKD1, CLIC1 | NOS1 587/4885NOS3 1421/4885NOS2 1392/4885 |
| US-20170002393-A1 | COMPOSITIONS AND METHODS FOR ANTIBODY PRODUCTION | TXNRD1, P4HB, CYBB | NOS1 668/4885NOS3 738/4885NOS2 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.